ATAI Stock Summary and Trading Ideas (Atai Life Sciences N.V. - Common Shares | NASDAQ:ATAI)

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.

Atai Life Sciences N.V. - Common Shares trades on the NASDAQ stock market under the symbol ATAI.

As of June 20, 2025, ATAI stock price climbed to $2.48 with 3,801,315 million shares trading.

ATAI has a beta of 1.42, meaning it tends to be more sensitive to market movements. ATAI has a correlation of 0.09 to the broad based SPY ETF.

ATAI has a market cap of $522.65 million. This is considered a Small Cap stock.

In the last 3 years, ATAI traded as high as $4.96 and as low as $1.03.

The top ETF exchange traded funds that ATAI belongs to (by Net Assets): VHT, PSIL, GWX.

ATAI has outperformed the market in the last year with a price return of +86.5% while the SPY ETF gained +10.6%. ATAI has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +81.0% and +2.9%, respectively, while the SPY returned +6.0% and -0.5%, respectively.

ATAI support price is $2.20 and resistance is $2.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATAI shares will trade within this expected range on the day.